Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson's disease

被引：2

作者：

Tall, P. ^{[1
,2
]}

Qamar, M. A. ^{[1
,2
]}

Batzu, L. ^{[1
,2
]}

Leta, V. ^{[1
,2
]}

Falup-Pecurariu, C. ^{[3
,4
]}

Chaudhuri, K. Ray ^{[1
,2
]}

机构：

[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, 16 De Crespigny Pk, London SE5 8AB, England

[2] Kings Coll Hosp London, Parkinsons Fdn Ctr Excellence, London, England

[3] Transilvania Univ, Fac Med, Brasov, Romania

[4] Cty Clin Hosp, Dept Neurol, Brasov, Romania

来源：

JOURNAL OF NEURAL TRANSMISSION | 2023年 / 130卷 / 11期

关键词：

Continous drug delivery; Parkinsons; Levodopa; Apomorphine; LCIG; LECIGON; Sleep; Park-sleep; CARBIDOPA INTESTINAL GEL; SUBCUTANEOUS APOMORPHINE INFUSION; NONMOTOR SYMPTOMS; LEVODOPA INFUSION; ROTIGOTINE; MOTOR; FLUCTUATIONS; MANAGEMENT; MULTICENTER; EFFICACY;

D O I：

10.1007/s00702-023-02640-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson's disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of motor and non-motor fluctuations partly related to pulsatile levodopa stimulation. Non-motor symptoms and fluctuations are ubiquitous in PD and include sleep dysfunction, a problem that occurs in over 90% of PD patients across all stages, from prodromal to palliative. In this review, we discuss the currently available and in development non-oral dopaminergic CDD strategies with a focus on their efficacy in the treatment of the burdensome sleep dysfunction in PD.

引用

页码：1443 / 1449

页数：7

共 50 条

[1] Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
P. Tall
M. A. Qamar
L. Batzu
V. Leta
C. Falup-Pecurariu
K. Ray Chaudhuri
[J]. Journal of Neural Transmission, 2023, 130 : 1443 - 1449
[2] Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?
Timpka, Jonathan
Henriksen, Tove
Odin, Per
[J]. MOVEMENT DISORDERS CLINICAL PRACTICE, 2016, 3 (03): : 221 - 229
[3] New non-oral drug delivery systems for Parkinson's disease treatment
Md, Shadab
Haque, Shadabul
Sahni, Jasjeet Kaur
Baboota, Sanjula
Ali, Javed
[J]. EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (03) : 359 - 374
[4] Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future
Gunes, Meliha
Karavana, Sinem Yaprak
[J]. TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 19 (03) : 343 - 352
[5] Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
Ray Chaudhuri K.
Qamar M.A.
Rajah T.
Loehrer P.
Sauerbier A.
Odin P.
Jenner P.
[J]. npj Parkinson's Disease, 2 (1)
[6] Continuous Drug Delivery in Parkinson’s Disease
Marina Senek
Dag Nyholm
[J]. CNS Drugs, 2014, 28 : 19 - 27
[7] Continuous Drug Delivery in Parkinson's Disease
Senek, Marina
Nyholm, Dag
[J]. CNS DRUGS, 2014, 28 (01) : 19 - 27
[8] Current oral and non-oral routes of antiepileptic drug delivery
Anderson, Gail D.
Saneto, Russell P.
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (10) : 911 - 918
[9] The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine
van Laar, Teus
Borgemeester, Robbert
[J]. PARKINSONISM & RELATED DISORDERS, 2016, 33 : S22 - S27
[10] Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease
van Wamelen, Daniel J.
Grigoriou, Sotirios
Chaudhuri, K. Ray
Odin, Per
[J]. JOURNAL OF PARKINSONS DISEASE, 2018, 8 : S65 - S72

← 1 2 3 4 5 →